In the clinical trial of the new drug, sacituzumab govitecan, about a third of the patients responded to treatment and the effect lasted up to eight months. The research was funded by the drug's maker.
from WebMD Health webmd
WE GAVE YOU 100% RICH AND VALUABLE HEALTH CONTENT/PRODUCTS RELATED ADDICTION, BEAUTY, DENTAL HEALTH, DIETS AND WEIGHT LOSS, SUPPLEMENTS AND NUTRITION, EXERCISE AND FITNESS, MENTAL HEALTH, MEDITATION, REMEDIES, SLEEP, AND DREAMS, SPIRITUAL HEALTH, STRENGTH TRAINING WOMEN HEALTH, MEN HEALTH, YOGA AND ALL GENERAL CALTOGORIES. WE CARE FOR YOU.
In the clinical trial of the new drug, sacituzumab govitecan, about a third of the patients responded to treatment and the effect lasted up to eight months. The research was funded by the drug's maker.